Evidence map›Paper›PMID 22684891›Full record

ArticleHepatology (Baltimore, Md.)2012

Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases.

Shashi Bala, Jan Petrasek, Shiv Mundkur, Donna Catalano, Ivan Levin, Jeanine Ward, Hawau Alao, Karen Kodys, Gyongyi Szabo

Open access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 356 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
356citing papers in PubMed, 1 pooled it
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

356 citing papers in PubMed, 1 synthesis or guideline pooled it, 622 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. PKM2: A gatekeeper in macrophage metabolic reprogramming.Journal of pharmaceutical analysis · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Asian journal of pharmaceutical sciences · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. miRNAs and Alcohol-Related Hepatitis.Current issues in molecular biology · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

296 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shashi BalaDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Jan Petrasek
Shiv Mundkur
Donna Catalano
Ivan Levin
Jeanine Ward
Hawau Alao
Karen Kodys
Gyongyi Szabo
University of Massachusetts Chan Medical School · US

Funding

MicroRNAs in Alcoholic Liver Disease Administrative SupplementR01AA020744 · NIAAA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SZABO, GYONGYI · 2011 to 2023
$5.3M
TLR4 Signaling in alcoholic liver diseaseR01AA017729 · NIAAA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SZABO, GYONGYI · 2009 to 2021
$4.3M
Toll like receptor - Mediated pathways in liver injuryR01DK075635 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SZABO, GYONGYI · 2008 to 2011
$1.4M
Innate immune signaling in alcoholic liver diseaseR56AA017729 · NIAAA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SZABO, GYONGYI · 2024 to 2025
$579k
NIAAA NIH HHS AA017729NIAAA NIH HHS AA020744NIAAA NIH HHS R01 AA017729NIAAA NIH HHS R01 AA020744NIAAA NIH HHS R56 AA017729NIDDK NIH HHS DK075635NIDDK NIH HHS R01 DK075635
6 · The paper itself

Abstract

unlabelledMicroRNAs are fine tuners of diverse biological responses and are expressed in various cell types of the liver. Here we hypothesized that circulating microRNAs (miRNAs) may serve as biomarkers of liver damage and inflammation. We studied miRNA-122, which is abundant in hepatocytes, and miR-155, -146a, and -125b, which regulate inflammation in immune cells in mouse models of alcoholic liver disease (ALD), drug (acetaminophen, APAP)-induced liver injury (DILI), and Toll-like receptor (TLR) 9+4 ligand-induced inflammatory cell-mediated liver damage. We found that serum/plasma miR-122 correlated with alanine aminotransferase (ALT) increases in the liver damage caused by alcohol, APAP, and TLR9 (CpG)+4 (LPS) ligands. MiR-155, a regulator of inflammation, was increased in serum/plasma in alcoholic and inflammatory liver injury. Alcohol failed to increase serum miR-122 in TLR4-deficient and p47phox-deficient mice that were protected from ALD. We found the most robust increase in plasma miR-122 in DILI and it correlated with the highest ALT levels. Consistent with the massive inflammatory cell infiltration in the liver, plasma miR-155 and miR-146a were significantly elevated after CpG+LPS administration. We show for the first time that, depending on the type of liver injury, circulating miRNAs are associated either with the exosome-rich or protein-rich compartments. In ALD and in inflammatory liver injury, serum/plasma miR-122 and miR-155 were predominantly associated with the exosome-rich fraction, whereas in DILI/APAP injury these miRNAs were present in the protein-rich fraction.

conclusionOur results suggest that circulating miRNAs may serve as biomarkers to differentiate between hepatocyte injury and inflammation and the exosome versus protein association of miRNAs may provide further specificity to mechanisms of liver pathology.

Indexed as

AcetaminophenAlanine TransaminaseAnimalsBiomarkersChemical and Drug Induced Liver InjuryCpG IslandsDisease Models, AnimalExosomesFemaleHepatitisHepatocytesLigandsLipopolysaccharidesLiverLiver Diseases, AlcoholicMiceAcetaminophenAlanine TransaminaseBiomarkersLigandsLipopolysaccharidesMicroRNAsMirn122 microRNA, mouseMirn125 microRNA, mouseMirn146 microRNA, mouseMirn155 microRNA, mouseToll-Like Receptor 4Toll-Like Receptor 9

Identifiers

PMID22684891
PMCPMC3486954
OpenAlexW2017857120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.